Fotoilustración: Pavlo Conchar/SOPA Images/LightRocket via Getty Images.
October 25, 2021 (Reuters) – Moderna Inc (MRNA.O) said on Monday, October 25th, its COVID-19 vaccine generated a strong immune response in children aged six to 11 years and that it plans to submit the data to global regulators soon.
Moderna said its two-dose vaccine generated virus-neutralizing antibodies in children and safety was comparable to what was previously seen in clinical trials of adolescents and adults. It cited interim data that has yet to be peer-reviewed.
It was unclear when U.S. regulators will weigh in on the shot. The Moderna COVID-19 vaccine is authorized for adults over the age of 18 years and is waiting for a response to its June application for children aged 12 through 17.
Moderna said that in its trial of 4,753 participants, side effects were mostly mild to moderate in severity. The most common side effects were fatigue, headache, fever and injection site pain.
The company statement did not disclose any new information about cases of heart inflammation called myocarditis, a known side effect of mRNA vaccines.
The shots were 50 microgram doses, half the strength used in the primary vaccine series for adults and the same as the booster dose authorized for adults. It is higher than the 10 microgram dose Pfizer is planning for its vaccine in children.
Both the Moderna and Pfizer/BioNTech vaccines have been linked to myocarditis in young men.
Some studies have suggested the rate of incidence in recipients of the Moderna vaccine may be higher than in Pfizer recipients, perhaps because of the stronger dose of vaccine.
Sweden has paused the use of the Moderna vaccine for younger age groups because of the higher risk of myocarditis.
While children rarely become seriously ill or die from COVID-19, some do develop rare complications, and COVID-19 cases in unvaccinated children have risen due to the contagious Delta variant.
Children can also spread the virus, infecting those who are not protected by vaccines and giving the virus more room to develop new variations.
Moderna shares rose 2% in morning trading.
Source: Reuters
The Yucatan Times Newsroom
Comments
more recommended stories
3 cases of dengue and 2 of influenza have been registered so far this year in YucatanWith the confirmation of a new.
Yucatan hoteliers glimpse encouraging outlook for the Christmas Holiday seasonMÉRIDA, Yucatán, (November 29, 2021).- For.
Scorpion venom molecules could fight bacteria and cancer cells: UNAMOne of the components of the.
While Ómicron threatens the world, AMLO summons the people to meet at Mexico City’s ZocaloWhile Ómicron threatens the world, AMLO.
Yari, 35 years old, decided to end her life in front of her relatives in MéridaThe woman spent about seven hours.
Croatian Mili Poljicak is proclaimed champion of the 34th Yucatán Junior Tennis World CupCroatian tennis player Mili Poljicak was.
American arrested in Cancun after his partner was found dead in a hotel roomCancun, Q.R. — An American man.
Tourism increases risk of contagion of COVID-19 of the new variant OmicronTravelers arrive to Mexico from countries.
Pharmaceuticals Value Soars By Omicron; earned USD$ 51.44 billionSpeculation about whether they will have.
Mexico reports 1,500 new cases of Covid-19 and 38 deaths in the last 24 hoursThe 10 states of the country.
Leave a Comment